N-Acetylcysteine in Preventing Contrast-Induced Nephropathy Assessed by Cystatin C

Basit Öğe Kaydı
dc.authoridErcan, Ertugrul/0000-0003-0480-4738
dc.authoridTURK, UGUR ONSEL/0000-0001-6348-6616
dc.authoridyildiz, serkan/0000-0003-1716-9884
dc.contributor.authorAlioglu, Emin
dc.contributor.authorSaygi, Serkan
dc.contributor.authorTurk, Ugur
dc.contributor.authorKirilmaz, Bahadir
dc.contributor.authorTuzun, Nurullah
dc.contributor.authorDuman, Can
dc.contributor.authorTengiz, Istemihan
dc.date.accessioned2025-01-27T20:50:06Z
dc.date.available2025-01-27T20:50:06Z
dc.date.issued2013
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAims: Prophylactic oral N-acetylcysteine (NAC) has been widely used for prevention of contrast-induced nephropathy (CIN). However, clinical studies have not been demonstrating this effect consistently because of evidence that NAC can alter serum creatinine levels without affecting glomerular filtration rate (GFR). We investigated NAC for the prevention of CIN by monitoring creatinine and cystatin C. Methods: We enrolled 113 patients (49 patients in NAC group and 64 patients in control group) with normal to subnormal GFR who were scheduled for cardiovascular procedures. Patients in NAC group receive acetylcysteine 600 mg twice a day, on the day before and on the day of cardiovascular procedure. All patients received a periprocedural intravenous infusion (volume expansion) of 1 ml/kg/h with 0.45% saline for 24 h (12 h before and 12 h after exposure to contrast medium). Serum cystatin C and creatinine levels were measured before and at 12, 24, and 48 h after procedure. Results: The incidence of cystatin C-based CIN was 28.5% (n = 14) in NAC and 23.4% (n = 15) in control group (p = 0.663) and serum creatinine-based CIN was 12.2% (n = 6) in NAC and 17.2% (n = 11) in control group (P= 0.468). In this study, oral NAC had no effect on the prevention of CIN in patients undergoing cardiovascular procedures. Conclusion: In this study, oral NAC administration does not reduce neither the incidence of cystatin C-based CIN nor serum creatinine-based CIN in patients undergoing cardiovascular procedures.
dc.description.sponsorshipTUBITAK (The Scientific and Technological Research Council of Turkey)
dc.description.sponsorshipThis study was supported by TUBITAK (The Scientific and Technological Research Council of Turkey).
dc.identifier.doi10.1111/j.1755-5922.2011.00309.x
dc.identifier.endpage173
dc.identifier.issn1755-5914
dc.identifier.issn1755-5922
dc.identifier.issue3
dc.identifier.pmid22212518
dc.identifier.scopus2-s2.0-84876476345
dc.identifier.scopusqualityQ1
dc.identifier.startpage168
dc.identifier.urihttps://doi.org/10.1111/j.1755-5922.2011.00309.x
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25412
dc.identifier.volume31
dc.identifier.wosWOS:000318039100008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-Hindawi
dc.relation.ispartofCardiovascular Therapeutics
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectContrast-induced nephropathy
dc.subjectcystatin C
dc.subjectN-acetylcysteine
dc.titleN-Acetylcysteine in Preventing Contrast-Induced Nephropathy Assessed by Cystatin C
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu